| Trial ID: | L5464 |
| Source ID: | NCT01588470
|
| Associated Drug: |
Pioglitazone
|
| Title: |
Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01588470/results
|
| Conditions: |
Type 2 Diabetes|Coronary Heart Disease
|
| Interventions: |
DRUG: pioglitazone
|
| Outcome Measures: |
Primary: Change in E to A Ratio, The E to A ratio is a marker of the function of the left ventricle of the heart. It represents the ratio of peak velocity flow in early diastole (the E wave) to peak velocity flow in late diastole caused by the atrial contraction (the A wave) This is measured using ultrasound-based cardiac imaging. In a healthy heart the E velocity is greater than the A velocity., Baseline and 6-months Post Treatment|Myocardial Glucose Uptake, Measurement of change in myocardial glucose uptake from baseline to 6 months of treatment with pitoglitazone, Baseline and 6-months Post Treatment | Secondary: Change in Hemoglobin A1c, Change in hemoglobin A1c levels measured at 6 months, Baseline and 6-months Post Treatment
|
| Sponsor/Collaborators: |
Sponsor: The University of Texas Health Science Center at San Antonio | Collaborators: Takeda Pharmaceuticals North America, Inc.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
130
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2006-06
|
| Completion Date: |
2011-12
|
| Results First Posted: |
2017-12-06
|
| Last Update Posted: |
2017-12-06
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT01588470
|
